GLP-1（グルカゴン様ペプチド-1）受容体作動薬の世界市場レポート 2024年

GLP-1（グルカゴン様ペプチド-1）受容体作動薬の市場規模は近年力強く成長しています。2023年の195億1,000万米ドルから2024年には210億1,000万米ドルへと、CAGR7.7％で拡大する見込みです。過去の期間における増加は、糖尿病の罹患率の増加、糖尿病管理の強化の重視、注射療法への患者の傾斜、臨床効果、安全性プロファイル、糖尿病研究の進歩などに起因しています。

GLP-1受容体作動薬の市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.6%で281億7,000万米ドルに成長します。予測期間に予想される拡大は、経口GLP-1療法の台頭、個別化医療への注力、糖尿病治療アルゴリズムへの統合、医療における患者中心のアプローチに起因すると考えられます。予測期間における主な動向としては、新興経済国における市場成長、新製剤の規制承認、個別化医療の重視、患者教育・啓発プログラム、競合状況のダイナミクスなどが挙げられます。

世界のGLP-1受容体作動薬市場は、糖尿病有病率の上昇により成長が見込まれています。血糖値の上昇を特徴とする糖尿病は、特に2型糖尿病においてGLP-1受容体作動薬が対処する疾患であり、体重減少や血糖コントロールの改善といった潜在的な利益をもたらします。米国国立医学図書館によると、2022年1月現在、20～79歳の世界糖尿病有病率は10.5％（5億3,660万人）と推定され、2045年には12.2％（7億8,320万人）に増加すると予測されています。その結果、糖尿病有病率の上昇がGLP-1受容体作動薬市場の原動力になると予想されます。

GLP-1受容体作動薬市場の成長は、個別化医療がますます重視されるようになることでさらに促進されると予想されます。個別化医療とは、個人の遺伝子やタンパク質関連情報に基づいて、予防、発見、治療のアプローチを調整することです。このアプローチにより、各患者の特定のニーズや嗜好に応じたGLP-1製剤や用量のカスタマイズが可能になります。米国食品医薬品局（FDA）が2022年に承認した個別化医薬品は12品目で、個別化医療連合（Personalized Medicine Coalition）の報告によれば、新たに承認された治療用分子実体の約34％を占めています。このように、個別化医療が重視されるようになっていることは、GLP-1受容体作動薬市場の拡大の触媒として機能しています。

北米は、2023年のGLP-1受容体作動薬市場で最大の地域でした。GLP-1受容体作動薬市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 市場促進要因・市場抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模と成長実績、2018～2023年
• 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のGLP-1受容体作動薬市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• トルリシティ
• オゼンピック
• ビクトーザ
• リベルサス
• その他
• 世界のGLP-1受容体作動薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界のGLP-1受容体作動薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院
• 専門クリニック
• その他

第7章 地域および国の分析

• 世界のGLP-1受容体作動薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のGLP-1受容体作動薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• GLP-1受容体作動薬市場の競合情勢
• GLP-1受容体作動薬市場の企業プロファイル
  • Novo Nordisk AS
  • Sanofi SA
  • Eli Lilly and Co
  • AstraZeneca plc
  • Pfizer Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Glucagon-like Peptide 1 Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glucagon-like peptide 1? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The glucagon-like peptide 1 market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Product: Trulicity; Ozempic; Victoza; Rybelsus; Other Types
• 2) By Route of Administration: Oral; Parenteral; Other Routes
• 3) By End-Users: Hospitals; Specialty Clinics; Other End Users
• Companies Mentioned: Novo Nordisk AS; Sanofi SA; Eli Lilly and Co; AstraZeneca plc; Pfizer Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Glucagon-such as peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.

The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.

The glucagon-such as peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucagon-such as peptide 1 market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $21.01 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%.The increase in the historical period can be attributed to the growing incidence of diabetes, emphasis on enhanced diabetes management, patient inclination toward injectable therapies, clinical effectiveness, safety profiles, and advancements in diabetes research.

The glucagon-such as peptide 1 market size is expected to see strong growth in the next few years. It will grow to $28.17 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The expansion expected in the forecast period can be attributed to the rise of oral GLP-1 therapies, a focus on personalized medicine, integration into diabetes treatment algorithms, and patient-centric approaches in healthcare. Major trends in the forecast period include market growth in emerging economies, regulatory approvals for new formulations, emphasis on personalized medicine, patient education and awareness programs, and dynamics in the competitive landscape.

The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.

The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.

Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.

Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, made a strategic acquisition of Protomer Technologies for approximately $1 billion. This acquisition positions Eli Lilly to leverage Protomer's next-generation protein therapeutics, particularly in the development of therapeutic peptides and proteins for individuals with diabetes. Protomer Technologies, a biotechnology company based in the US, specializes in protein therapeutics, including the creation of glucose-responsive insulin for diabetes therapy.

Major companies operating in the glucagon-such as peptide 1 market report are Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd., Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd., Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc., ConjuChem Biotechnologies, MannKind Corporation,, Provention Bio Inc., Regeneron Pharmaceuticals

North America was the largest region in the glucagon-such as peptide 1 market in 2023. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Glucagon-like Peptide 1 Market Size and Growth

• 5.1. Global Glucagon-like Peptide 1 Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Glucagon-like Peptide 1 Market Segmentation

• 6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Trulicity
• Ozempic
• Victoza
• Rybelsus
• Other Types
• 6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Other End Users

7. Glucagon-like Peptide 1 Market Regional And Country Analysis

• 7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Glucagon-like Peptide 1 Market

• 8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Glucagon-like Peptide 1 Market

• 9.1. China Glucagon-like Peptide 1 Market Overview
• 9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Glucagon-like Peptide 1 Market

• 10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Glucagon-like Peptide 1 Market

• 11.1. Japan Glucagon-like Peptide 1 Market Overview
• 11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Glucagon-like Peptide 1 Market

• 12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Glucagon-like Peptide 1 Market

• 13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Glucagon-like Peptide 1 Market

• 14.1. South Korea Glucagon-like Peptide 1 Market Overview
• 14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Glucagon-like Peptide 1 Market

• 15.1. Western Europe Glucagon-like Peptide 1 Market Overview
• 15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Glucagon-like Peptide 1 Market

• 16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Glucagon-like Peptide 1 Market

• 17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Glucagon-like Peptide 1 Market

• 18.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Glucagon-like Peptide 1 Market

• 19.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Glucagon-like Peptide 1 Market

• 20.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Glucagon-like Peptide 1 Market

• 21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview
• 21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Glucagon-like Peptide 1 Market

• 22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Glucagon-like Peptide 1 Market

• 23.1. North America Glucagon-like Peptide 1 Market Overview
• 23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Glucagon-like Peptide 1 Market

• 24.1. USA Glucagon-like Peptide 1 Market Overview
• 24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Glucagon-like Peptide 1 Market

• 25.1. Canada Glucagon-like Peptide 1 Market Overview
• 25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Glucagon-like Peptide 1 Market

• 26.1. South America Glucagon-like Peptide 1 Market Overview
• 26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Glucagon-like Peptide 1 Market

• 27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Glucagon-like Peptide 1 Market

• 28.1. Middle East Glucagon-like Peptide 1 Market Overview
• 28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Glucagon-like Peptide 1 Market

• 29.1. Africa Glucagon-like Peptide 1 Market Overview
• 29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

• 30.1. Glucagon-like Peptide 1 Market Competitive Landscape
• 30.2. Glucagon-like Peptide 1 Market Company Profiles
  • 30.2.1. Novo Nordisk AS
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Sanofi SA
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Eli Lilly and Co
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Pfizer Inc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Glucagon-like Peptide 1 Market Competitive Benchmarking

32. Global Glucagon-like Peptide 1 Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Glucagon-like Peptide 1 Market Future Outlook and Potential Analysis

• 34.1 Glucagon-like Peptide 1 Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Glucagon-like Peptide 1 Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Glucagon-like Peptide 1 Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer